Inverness extends bond exchange deadline
May 26, 2010 by MassDevice staff
With all but $2 million of the notes already turned in, Inverness Medical Innovations gives stragglers an extra two weeks to exchange unregistered notes maturing in February 2012.
Inverness Medical Innovations Inc. (NYSE:IMA) is giving a handful of stragglers a little extra time to cash in their unregistered bonds.
The Waltham, Mass.-based diagnosis, monitoring and health management firm is extending until June 4 the tender period for note-holders to turn in Inverness bonds maturing in February 2016. The tender period had been set to expire at 5 p.m May 24, with about 98 percent of the note-holders making that deadline.
- Login to post comments
-
Permalink
RECENT BLOG POSTS
- A cure for coffee breath?
- A Goldilocks approach to leaky blood vessels: Not too stiff, but not too loose
- Optimizing electronic medication administration records
- A bold new vision for Meditech
- Medtech storytelling in the era of comparative effectiveness
- Medical device sales: Wright Medical's pilot program on rep-less sales process worth watching
- Raising an early warning in the ICU: T3
- Staff shakeup underway at Russian medical device regulator
- Heart Rhythm Society 2013 Scientific Session wrap-up
- Physician blogger insights on social media
Navigation
NEWS
Pluristem launches Phase I clinical trial to treat tendonitis with stem cells
Pluristem is seeking clinical proof that stem cell therapy can benefit patients with chronic...
GE Healthcare unveils soft tissue imaging technology
GE Healthcare introduces Mavric SL, a novel magnetic resonance imaging technique for joint...
Hip implants: Johnson & Johnson's DePuy will stop selling metal-on-metal implants
Johnson & Johnson subsidiary DePuy Orthopaedics plans to phase out sales of all of its metal-on-...
Combat Medical Systems wins 1st-of-its kind approval for tourniquet
The FDA approves a novel combat-ready clamp to treat wounds most commonly associated with roadside or...
Vascular Solutions CEO: Boston Scientific's alleged patent infringement 'blatant'
Vascular Solutions CEO Howard Root says alleged infringement by Boston Scientific's Guidezilla "is...
